Frost & Sullivan Independent Equity Research
Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.
![logo_cellect-biotech logo_cellect-biotech](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/logo_cellect-biotech-nx7oenqvj2y33m2uhxiuo5wv2s7xme8mc1ykanhgzk.jpg)
Company: Cellect
Sector: Biotechnology
Report type: Q2-2018 Update Report
Published on: 20 August, 2018